In a potential setback for Roche (RHHBY), five patients taking its new Hemlibra hemophilia treatment have died, raising uncertainty about the safety of the medication, even though the company maintained its drug did not cause any of the deaths.

Over the past two years, one patient died during a late-stage clinical trial and the others died while taking Hemlibra as part of a compassionate use program, which provides access to experimental medicines before regulatory approval.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • May I observe that people wonder wht ‘PHARMA” is against these right-to-try initiatives? How about ‘stuff happens?” – “Over the past two years, two patients died while taking Hemlibra as part of a compassionate use program, which provides access to experimental medicines before regulatory approval.”
    And so Roche made the drug available and what is their reward? I’m not trying to deify them but nothing complicated is ever a zero sum game. The fact of there events is and will be counted against them. I would say how dumb did the US House have to be to pass something like that but …. why ask?

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy